← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 369개
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CLL1-CD33 cCAR T cells (CLL1-CD33 cCAR T cells)

Hematologic Malignancy; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleMEI HENGPhase 1

CT0991 CAR-T cells infusicn (CT0991 CAR-T cells infusicn)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleChi Kong LiPhase 2

CUCART19 (CUCART19)

Lymphoma, Nonhodgkin; Leukemia, Lymphocytic · Lymphoma, Nonhodgkin

#LymphomaNonhodgkin#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleJohn ListerPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous))

B-Cell Lymphoma; B Acute Lymphoblastic Leukemia · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleSouthwest Hospital, ChinaPhase 2

Chimeric Antigen Receptor Modified T cells Targeting CD19 (Chimeric Antigen Receptor Modified T cells Targeting CD19)

Leukemia; Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
ADCBiologicstaleEverett MeyerPhase 2

CliniMACS CD34 Reagent System (CliniMACS CD34 Reagent System)

Leukemia, Acute; Chronic Myelogenous Leukemia (CML) · CD3

#CD3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
AntibodystaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMasonic Cancer Center, Universi…Phase 2

Donor TCR α/β-depleted Graft/ATG (Donor TCR α/β-depleted Graft/ATG)

Acute Myeloid Leukemia; Myelodysplastic Syndrome · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, Inc., a Bris…Phase 1

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

Chronic Lymphocytic Leukemia (CLL); Relapsed · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleRoswell Park Cancer InstitutePhase 1

EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T-lymphocytes)

Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBeijing Boren HospitalPhase 1

Efficacy of LCAR-T2C CAR-T cells (Efficacy of LCAR-T2C CAR-T cells)

T Cell Lymphoma; T-cell Leukemia · T Cell Lymphoma

#TCellLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBaylor College of MedicinePhase 1

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells (Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED

14 / 19 페이지

← 이전다음 →